Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Reduced Dose Post Transplant Cyclophosphamide After Haploidentical Hematopoietic Stem Cell Transplant in Hematological Malignancies

NCT07719946 is registered in ClinicalTrials.gov with Tata Memorial Centre as lead sponsor.

NCT NCT07719946
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07719946 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Reduced Dose Post Transplant Cyclophosphamide After Haploidentical Hematopoietic Stem Cell Transplant in Hematological Malignancies
Lead sponsor
Tata Memorial Centre
Phase
Phase 2
Overall status
Recruiting
Start date
March 26, 2025
Completion date
November 12, 2028
Enrollment
20 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

haploidentical hematopoietic stem cell transplant, hematological malignancies